PD-1 Checkpoint Inhibitor Shows Promise for Anal Cancer
Zynyz (retifanlimab) plus chemotherapy significantly improved progression-free survival in advanced anal cancer patients, according to a Phase III trial presented at ESMO 2024, suggesting it may become a new standard of care. The trial included people with HIV and showed a 37% reduction in disease progression risk, with Zynyz recipients experiencing longer progression-free survival and response duration compared to placebo recipients. Incyte plans to seek FDA approval for Zynyz in anal cancer by year-end.
Related Clinical Trials
Reference News
Zynyz (retifanlimab) plus chemotherapy significantly improved progression-free survival in advanced anal cancer patients, according to a Phase III trial presented at ESMO 2024, suggesting it may become a new standard of care. The trial included people with HIV and showed a 37% reduction in disease progression risk, with Zynyz recipients experiencing longer progression-free survival and response duration compared to placebo recipients. Incyte plans to seek FDA approval for Zynyz in anal cancer by year-end.